EcoDrugPlus

Notch Receptor 3

Ensembl ID : ENSCHAG00000018234
Gene Symbol: NOTCH3
1 Cross references
194 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSCHAG00000005322
Gene Symbol: NFKB1
1 Cross references
202 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSCHAG00000020615
Gene Symbol: NR1H4
3 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSCHAG00000024937
Gene Symbol: NR1H3
1 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSCHAG00000006120
Gene Symbol: NR3C1
3 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 2

Ensembl ID : ENSCHAG00000009682
Gene Symbol: NR3C2
1 Cross references
211 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSCHAG00000014031
Gene Symbol: NOD2
1 Cross references
166 Possible Orthologues:

Nucleotide-Binding Oligomerization Domain Containing 2

Ensembl ID : ENSCHAG00000015313
Gene Symbol: NOD2
1 Cross references
165 Possible Orthologues:

Opiate Receptor-Like 1

Ensembl ID : ENSCHAG00000027504
Gene Symbol: OPRL1
1 Cross references
191 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSCHAG00000002491
Gene Symbol: OPRD1
3 Cross references
187 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSCHAG00000012227
Gene Symbol: OPRK1
3 Cross references
197 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSCHAG00000022325
Gene Symbol: OPRM1
3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).